VRDN: Viridian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
Stocks in this Quantisnow insightHealth Care
Historical context for VRDN
Across the 15 sessions after earlier VRDN headlines, the stock closed higher 9 times and lower 6 times, with a median move of 2.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VRDN | SPY |
|---|---|---|---|
| May 5, 2026 | Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progressand 1 other headline that session | +33.4% | +0.8% |
| Mar 30, 2026 | Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease | -32.3% | -0.3% |
| Feb 26, 2026 | Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results | +1.9% | -0.6% |
| Jan 9, 2026 | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +4.7% | +0.7% |
| Jan 6, 2026 | Viridian Therapeutics Prepares for Transformational 2026 | +1.7% | +0.6% |
| Dec 22, 2025 | Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease | +1.7% | +0.6% |
Quantisnow market dataNASDAQ
VRDN
Viridian Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for VRDN
Full VRDN profile on Quantisnow Follow VRDN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time